Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entospletinib - Kronos Bio

Next Previous
Drug Profile

Entospletinib - Kronos Bio

Alternative Names: ENTO; GS-9973

Latest Information Update: 19 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CGI Pharmaceuticals
  • Developer CGI Pharmaceuticals; Gilead Sciences; Kronos Bio; Lymphoma Academic Research Organisation
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Imidazoles; Indazoles; Morpholines; Pyrazines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Cancer; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 10 Dec 2022 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 14 Nov 2022 Kronos Bio discontinues a phase III AGILITY trial in Acute myeloid leukaemia (Combination therapy, First-line therapy, Newly diagnosed) in Brazil, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Multinational, Poland, Russia, South Korea, Spain, Ukraine, USA (PO) (NCT05020665)
  • 08 Nov 2022 Kronos Bio plans to discontinue the phase III trial and close enrollment in the fourth quarter of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top